(Circulation. 1997;96:621-627.)
© 1997 American Heart Association, Inc.
Articles |
Inhibition of Vascular Smooth Muscle Cell Proliferation and Neointimal Accumulation by Adenovirus-Mediated Gene Transfer of Cytosine Deaminase
From the Cardiology Branch (R.L.H., M.A.S.R., A.M.D., R.J.G., S.E.E., T.F.), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md, and Division of Pulmonary and Critical Care (E.A.H., R.G.C.), New York Hospital–Cornell Medical Center, New York, NY.
Correspondence to Toren Finkel, MD, PhD, Cardiology Branch, National Institutes of Health, 10 Center Dr MSC 1650, Bldg 10, Room 7B15, Bethesda, MD 20892-1650. E-mail finkelt{at}gwgate.nhlbi.nih.gov
Background Restenosis remains a significant problem after balloon angioplasty. Previous studies have demonstrated that recombinant adenoviruses are efficient vectors for gene transfer to the arterial wall and can be used to inhibit the proliferative aspect of restenosis. We sought to extend these observations using AdCMV.CD, an adenovirus that encodes cytosine deaminase (CD) and is capable of metabolizing 5-fluorocytosine (5-FC) to 5-fluorouracil.
Methods and Results Infection of vascular smooth muscle cells (VSMC) with AdCMV.CD increases by two to three orders of magnitude the growth-inhibitory effects of 5-FC. The degree of VSMC inhibition in vitro was a function of 5-FC concentration and the level of CD expression. Cells infected with AdCMV.CD exhibited a profound bystander effect on the growth of neighboring cells, which did not require direct cell-to-cell contact. The predominant effect of AdCMV.CD on growth of VSMC appeared to be cytostatic, not cytotoxic. Assessment of this strategy in a rabbit femoral artery model of balloon-induced injury demonstrated that compared with animals in either of two control groups, animals treated with the active combination of infection with AdCMV.CD and 1-week treatment with parenteral 5-FC had a significant reduction at 30 days in the neointimal-to-medial ratio.
Conclusions Our results suggest that adenovirus-mediated gene transfer of CD along with 5-FC administration may be a useful strategy to treat the proliferative aspects of restenosis.
Key Words: angioplasty • adenoviruses • muscles, smooth
This article has been cited by other articles:
 |
|
 |
|
  Y. Chen, R. C. Budd, R. J. Kelm Jr, B. E. Sobel, and D. J. Schneider Augmentation of Proliferation of Vascular Smooth Muscle Cells by Plasminogen Activator Inhibitor Type 1 Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1777 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Zuckerbraun and E. Tzeng Vascular Gene Therapy: A Reality of the 21st Century Arch Surg, July 1, 2002; 137(7): 854 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Meyerson, C. L. Skelly, M. A. Curi, and L. B. Schwartz Gene Therapy for Cardiovascular Disease Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2000; 4(4): 289 - 300. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Hoffmann and G.S. Mintz Coronary in-stent restenosis--predictors, treatment and prevention Eur. Heart J., November 1, 2000; 21(21): 1739 - 1749. [PDF]
|
|
|
|
 |
|
 M. R. Kibbe, T. R. Billiar, and E. Tzeng Gene Therapy for Restenosis Circ. Res., April 28, 2000; 86(8): 829 - 833. [Full Text] [PDF]
|
|
|
|
 |
|
 M. O Hiltunen, M. P Turunen, M. Laitinen, and S. Yla-Herttuala Insights into the molecular pathogenesis of atherosclerosis and therapeutic strategies using gene transfer Vascular Medicine, February 1, 2000; 5(1): 41 - 48. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Indolfi, A. Cioppa, E. Stabile, E. Di Lorenzo, G. Esposito, A. Pisani, A. Leccia, L. Cavuto, A. M. Stingone, A. Chieffo, et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury J. Am. Coll. Cardiol., January 1, 2000; 35(1): 214 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Li and G. Brooks Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy? Eur. Heart J., March 2, 1999; 20(6): 406 - 420. [PDF]
|
|
|
|
 |
|
 M. Sawada, H. Yanamoto, I. Nagata, N. Hashimoto, I. Nakahara, Y. Akiyama, H. Kikuchi, and R. L. Macdonald Prevention of Neointimal Formation by a Serine Protease Inhibitor, FUT-175, After Carotid Balloon Injury in Rats • Editorial Comment Stroke, March 1, 1999; 30(3): 644 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Kullo, R. D. Simari, and R. S. Schwartz Vascular Gene Transfer : From Bench to Bedside Arterioscler Thromb Vasc Biol, February 1, 1999; 19(2): 196 - 207. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Heckenkamp and G. M. Lamuraglia Intimal Hyperplasia, Arterial Remodeling, and Restenosis: An Overview Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1999; 11(2): 71 - 94. [Abstract] [PDF]
|
|
|
|
|
|
S. Baek and K. L. March Gene Therapy for Restenosis : Getting Nearer the Heart of the Matter Circ. Res., February 23, 1998; 82(3): 295 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Qian, K. Channon, V. Neplioueva, Q. Wang, M. Finer, L. Tsui, S. E. George, and J. McArthur Improved Adenoviral Vector for Vascular Gene Therapy : Beneficial Effects on Vascular Function and Inflammation Circ. Res., May 11, 2001; 88(9): 911 - 917. [Abstract] [Full Text] [PDF]
|
|